serine peptidase inhibitor Kazal type 2Genealiases: HUSI-II · SPGF29
Q-omics provides the consensus-scored SPINK2 profile across patient tissues and cancer cell-line models. SPINK2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SPINK2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, SPINK2 RNA expression shows 15,223 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, COAD, and TGCT as cancer lineages where SPINK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINK2 survival associations across molecular data types. SPINK2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINK2 RNA expression–survival associations across cancer types. High SPINK2 expression shows unfavorable associations in SCLC, LAML and UVM, but favorable associations in MESO, LUAD and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for SPINK2 RNA expression.
This table summarizes SPINK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPINK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINK2 shows lower tumor expression in COAD, READ, STAD and BRCA and higher tumor expression in THCA and LUAD. The COAD box plot shows higher SPINK2 RNA expression in normal versus tumor tissue (log2 FC = −2.407, t-test p < 0.001).
This table shows molecular features associated with SPINK2 in patient tissues and cancer cell lines. In patient samples, SPINK2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPINK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
